IndustryCompany release

ADC Therapeutics reports $21M Zynlonta Q3 sales as restructuring extends cash runway into 2029

🇺🇸 ADC Therapeutics SA (ADCT) · Mon 09 Nov 2026

The company completed an $86.6 million PIPE and amended its royalty and loan agreements in October, while partner Tanabe Pharma filed for Zynlonta approval in Japan.

ADC Therapeutics reported third-quarter 2026 results on 9 November, showing net Zynlonta product revenue of $21.0 million for the period ended 30 September. Cash stood at $189.2 million.

In October the company completed a restructuring that included an $86.6 million private investment in public equity (PIPE) financing, along with amended royalty and loan agreements. ADC Therapeutics says these steps extend its expected cash runway into 2029.

On the regulatory front, partner Tanabe Pharma has filed a marketing authorisation application with Japan's Ministry of Health, Labour and Welfare (MHLW). The filing covers Zynlonta in relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more systemic therapies. Tanabe has also sublicensed the product to Nippon Shinyaku.

Clinical data will feature at the American Society of Hematology (ASH) annual meeting in December, where five oral presentations on Zynlonta have been accepted.

What it means for your team

  • Regulatory teams tracking lymphoma therapies should note the MHLW filing in third-line-plus relapsed or refractory DLBCL, which opens a Japanese review for Zynlonta.
  • The Tanabe-to-Nippon Shinyaku sublicence is relevant for anyone mapping local marketing authorisation holder and commercial responsibilities in Japan.
  • Market-access and competitive-intelligence teams may want to follow the five ASH oral presentations in December for new Zynlonta data.

Company's press release (SEC filing): ADC Therapeutics SA ↗

Article written by VigiEye from the official source (ADC Therapeutics SA). Claims are the company's own. AI-assisted; check the source before acting.

More Industry All →